Impact BioMedical Inc. IBO
AMEX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 400.00% | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 400.00% | -- | -- | -- | -- |
| Cost of Revenue | 42,300.00% | -- | -- | -- | -- |
| Gross Profit | -6,583.33% | -- | -- | -- | -- |
| SG&A Expenses | 18.88% | 65.52% | 8.04% | 67.79% | 130.59% |
| Depreciation & Amortization | 1.06% | 2.23% | 2.32% | 1.61% | 1.07% |
| Other Operating Expenses | -19.85% | 29.12% | 140.46% | 183.85% | 222.13% |
| Total Operating Expenses | 23.01% | 53.57% | 26.54% | 9.50% | 15.44% |
| Operating Income | -22.38% | -52.50% | -25.60% | -8.82% | -15.25% |
| Income Before Tax | 95.31% | 38.23% | 41.59% | -4,125.96% | -790.95% |
| Income Tax Expenses | -7,918.18% | -7,918.18% | -7,918.18% | -- | -- |
| Earnings from Continuing Operations | 102.01% | 48.61% | 52.09% | -4,128.96% | -791.71% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -72.92% | -51.35% | -48.39% | -25.40% | -33.33% |
| Net Income | 102.05% | 48.60% | 52.10% | -3,906.29% | -805.70% |
| EBIT | -22.38% | -52.50% | -25.60% | -8.82% | -15.25% |
| EBITDA | 5.68% | -14.42% | 24.65% | 30.08% | 0.53% |
| EPS Basic | 97.25% | 42.17% | 38.08% | -2,743.02% | -1,242.48% |
| Normalized Basic EPS | 88.85% | -4,750.05% | -3,695.22% | -1,169.75% | -339.95% |
| EPS Diluted | 97.36% | 49.32% | 45.54% | -2,023.20% | -1,293.04% |
| Normalized Diluted EPS | 91.37% | -355.81% | -403.87% | -836.14% | -468.79% |
| Average Basic Shares Outstanding | 571.90% | 392.36% | 193.42% | -21.41% | -60.61% |
| Average Diluted Shares Outstanding | 194.69% | 110.22% | 21.93% | -60.54% | -10.20% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |